Pfizer's $1.25B Bet on a Chinese Cancer Drug Is Moving Scarily Fast
Pfizer went from signing a $1.25 billion deal with China's 3SBio to Phase 3 readiness in just six months, an almost unheard-of pace for a licensed oncology asset. The drug, SSGJ-707, is part of a $40 billion industry-wide scramble to own the PD-1/VEGF bispecific space before the immunotherapy patent cliff hits.
Six Months. That's It.
Most licensed drugs sit in limbo for years after a deal closes. Regulatory handoffs, manufacturing headaches, internal politics: the list of speed bumps is long. So when Pfizer closed its $1.25 billion upfront deal with China's 3SBio in mid-2025 and had Phase 3 trials essentially ready to launch by early 2026, people in the industry started paying attention.
We're talking cleared INDs and first manufacturing batches produced. All within roughly six months of signing the check. For context, that timeline is like remodeling your kitchen and actually finishing on schedule. It doesn't happen.
The drug in question is SSGJ-707, a bispecific antibody that hits two targets at once: PD-1 and VEGF. And the speed of this rollout tells you everything about how badly Pfizer wants it to work.
Two Birds, One (Very Expensive) Stone
Let's unpack what SSGJ-707 actually does, because the science here is genuinely clever.
PD-1 is a checkpoint on your immune cells. Tumors exploit it like a "do not disturb" sign, telling your T cells to stand down. Blocking PD-1 (which drugs like Keytruda already do) rips that sign off and lets your immune system attack. VEGF, on the other hand, is a protein that helps tumors build their own blood supply, essentially constructing highways for nutrients and growth.
Most oncologists already combine PD-1 blockers with VEGF inhibitors as separate infusions. SSGJ-707 bundles both into a single molecule. Think of it like a combination lock that turns two tumblers simultaneously instead of one at a time. The bispecific format also creates a cooperative binding effect: when VEGF is present, the drug forms multimers that actually enhance its grip on PD-1. The more hostile the tumor environment, the harder SSGJ-707 works.
Early Phase 2 data from Chinese trials showed response rates up to 81.3% in non-small cell lung cancer (NSCLC), with a 100% disease control rate. Those are eye-popping numbers for a monotherapy, even in early-stage data that deserves healthy skepticism.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The $20 Billion Land Grab
Pfizer isn't chasing this molecule in a vacuum. The PD-1/VEGF bispecific category has become the hottest arms race in oncology, and global pharma companies have collectively thrown over $20 billion in deal value at it.
The starting gun was ivonescimab, developed by Akeso and partnered with Summit Therapeutics. In September 2024, it became the first drug ever to beat Keytruda head-to-head in a Phase 3 lung cancer trial on progression-free survival. That single data readout sent shockwaves through boardrooms worldwide. Keytruda generates roughly $29.5 billion in annual revenue; suddenly, its throne looked shakeable.
The dealmaking frenzy that followed has been staggering:
AstraZeneca reportedly circled a deal with Summit worth up to $15 billion for ivonescimab
Bristol Myers Squibb paid $11 billion for BioNTech's PD-L1/VEGF bispecific
AbbVie locked up RemeGen's candidate for $5.6 billion
Merck grabbed LaNova's asset for $588 million
Pfizer's $1.25 billion upfront for SSGJ-707 looks almost modest by comparison. But the total deal could reach approximately $6 billion when you add up to $4.8 billion in milestone payments, tiered double-digit royalties, and a $100 million equity investment in 3SBio. There's also a $150 million option for Pfizer to extend rights into China.
Every major pharma company now wants a PD-1/VEGF bispecific on its shelf. It's become table stakes for oncology portfolios.
Why Pfizer Is Running, Not Walking
To understand the urgency, you have to understand the hole Pfizer is trying to fill.
Revenues cratered from a $100.3 billion peak in 2022 (thank you, COVID products) to $63.6 billion in 2024. The company's $43 billion acquisition of Seagen in late 2023 gave it a strong antibody-drug conjugate (ADC) platform, but Pfizer needs more shots on goal. Management has targeted $25 billion in risk-adjusted revenue by 2030 from business development deals made since 2022.
Oncology is the centerpiece of that plan. Pfizer allocated about 40% of R&D spending to cancer in 2025, and the company is planning roughly 20 key pivotal trials in 2026. Four of those are specifically for SSGJ-707.
The manufacturing hustle tells the same story. Pfizer is producing drug substance at its Sanford, North Carolina facility and drug product in McPherson, Kansas. Having domestic manufacturing locked down this quickly for a China-licensed asset is unusual and deliberate. It sidesteps geopolitical concerns about supply chain dependence on Chinese production, which has become a real sensitivity for drugs originating from Chinese biotechs.
The Fine Print (and the Real Risk)
For all the excitement, there are legitimate questions hovering over this entire drug class.
The biggest: overall survival data remains inconclusive. Ivonescimab beat Keytruda on progression-free survival, meaning patients went longer before their cancer grew. But living longer without disease progression isn't the same as living longer, period. Regulators (and payers) will eventually want to see that survival gap. Until then, the blockbuster thesis for PD-1/VEGF bispecifics rests partly on faith.
There's also the China-to-global translation risk. SSGJ-707's impressive early data comes from Chinese patient populations. Genetic diversity, treatment histories, and healthcare contexts differ across regions. Global Phase 3 trials will need to replicate those results in Western populations, starting with NSCLC patients in the United States.
And competition is fierce. With 17-plus clinical assets in the PD-1/VEGF space (most originating from China) and multiple global Phase 3 studies planned, the window to establish first-mover advantage is closing fast. The PD-(L)1 patent cliff around 2028 adds even more urgency; every big pharma company needs its next-generation immunotherapy locked in before the generics flood arrives.
The Bottom Line
Pfizer moved faster on SSGJ-707 than almost anyone expected. Six months from deal close to Phase 3 readiness is a pace that signals genuine conviction, not just corporate optimism. The company is betting that this bispecific can become a pillar of its post-COVID oncology rebuild, and it's spending accordingly.
But conviction and clinical proof are two different things. The Phase 3 data (likely reading out through 2027) will determine whether that $1.25 billion upfront was a bargain or a very expensive lottery ticket. With billions in industry capital chasing the same biological insight, whoever gets definitive survival data first will own one of the most valuable franchises in cancer medicine.
Pfizer clearly doesn't intend to be second.
Clinical & Regulatory
4 min read
The Biotech That Lost 80% of Its Value in a Day (and Is Betting Everything on One More Shot)
Vistagen's stock once surged 1,272% on a single trial result, then cratered 80% when the next one flopped. Now the company has cut 20% of its staff and is betting everything on one final Phase 3 readout that could save or sink the whole operation.
